This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Abbott's (ABT) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation contributed to Abbott's (ABT) Q1 revenues.
Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing
by Zacks Equity Research
Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.
Insulet's (PODD) New Omnipod, Strategic Moves Drive Growth
by Zacks Equity Research
Insulet (PODD) has been progressing well with respect to its four-pillar strategy, where the first two pillars include expanding access and awareness and delivering consumer-focused innovation.
Here's Why You Should Invest in Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), led by the strong potential in the company's dental technology joint venture, Henry Schein One.
Abbott (ABT) Gets FDA Clearance for FreeStyle Libre 3 Reader
by Zacks Equity Research
Abbott (ABT) receives the FDA clearance for a standalone reader to be used for the FreeStyle Libre 3 iCGM system.
UnitedHealth (UNH) Beats on Q1 Earnings, Ups EPS 2023 View
by Zacks Equity Research
Strong membership growth and consistent management of medical and operating costs aid UnitedHealth's (UNH) UnitedHealthcare unit in the first quarter.
Bio-Rad (BIO) Rises 6.5% Since Q4 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Bio-Rad's (BIO) strong global presence and stable solvency position.
Globus' (GMED) NUVA Buyout Seems Strategic, Cost Woe Stays
by Zacks Equity Research
Globus Medical (GMED) and NuVasive (NUVA) are currently planning to combine in an all-stock transaction to create a global musculoskeletal company.
Amedisys (AMED) New Buyouts Aid Growth, CMS Ruling Unfavorable
by Zacks Equity Research
For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.
Walgreens (WBA) Declares Partnership With Prothena Corporation
by Zacks Equity Research
Walgreens (WBA) collaborates with Prothena Corporation to support patient awareness, participation and representation in a clinical trial of Prothena's Alzheimer's drug candidate, PRX012.
Myriad Genetics' (MYGN) New Pact to Boost Precision Medicine
by Zacks Equity Research
Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.
Are Investors Undervaluing Avanos Medical (AVNS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BRKR's Canopy Biosciences Partners With Enable Medicine
by Zacks Equity Research
BRKR's Canopy Biosciences collaborates with Enable Medicine to bring advanced spatial analysis pipelines to the Canopy CellScape System for high-plex spatial biology.
Brookdale (BKD) Q1 Adjusted EBITDA to Beat View, Occupancy Up
by Zacks Equity Research
Brookdale Senior Living (BKD) witnesses 17 straight months of year-over-year increases in weighted average occupancy level.
Illumina (ILMN) Partners With Henry Ford Health for NGS Test
by Zacks Equity Research
Illumina (ILMN) collaborates with Henry Ford Health to conduct a series of studies that is likely to focus on the genetic drivers of cardiovascular disease.
Here's Why Investors Should Buy Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on robust growth in Life Science and Clinical Diagnostics arms.
Thermo Fisher (TMO) Expands to Boost Commercial Manufacturing
by Zacks Equity Research
Thermo Fisher's expansion in Bourgoin is built on the company's investments in small molecule solutions.
Henry Schein (HSIC) Acquires Majority Stake in Biotech Dental
by Zacks Equity Research
Henry Schein (HSIC) announces that the completion of the Biotech Dental partnership brings forth the company's several important solutions to customers.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) strength in the Companion Animal Group business.
CVS Health (CVS) Team Up to Treat Digestive Disorder Virtually
by Zacks Equity Research
CVS Health's (CVS) recent partnership with Oshi makes it possible for its members to receive coordinated virtual digestive treatment.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Quest Diagnostics (DGX) Advances Access to Transplant Services
by Zacks Equity Research
Quest Diagnostics' (DGX) upgrade to advanced diagnostics and support services is likely to feature personalized patient access to service centers and mobile phlebotomists.
Is Avanos Medical (AVNS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Avanos Medical (AVNS) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
QIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers
by Zacks Equity Research
In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.